Storys zum Thema Krebs

Schweizerischer Nationalfonds / Fonds national suisse

Graphene nanoflakes: a new tool for precision medicine

Bern (ots) - Chemists funded by the SNSF have created a new compound for flexible drug delivery that specifically targets prostate cancer cells. Incorporating four different molecules, the compound prevents tumour cells from multiplying, can be detected by medical imaging and has staying power in the bloodstream. Usually, a drug is administered indiscriminately and most of it does not reach the diseased tissues. The goal ...

Sophia Genetics

ADC Therapeutics and SOPHiA GENETICS Partner for Biomarker Discovery in Pivotal Phase II Clinical Trial

Study to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) Lausanne, Switzerland (ots/PRNewswire) - ADC Therapeutics, an oncology drug discovery and development company that specializes in the development ...

Merck Healthcare Germany GmbH

Merck Presents Updated Results for Investigational Therapy Tepotinib Demonstrating Durable Clinical Response in Patients with Advanced NSCLC with METex14 Skipping Mutations

ASCO Abstract # Tepotinib (MET kinase inhibitor): 9005 Not intended for UK- , Canada- or US-based media Darmstadt, Germany (ots/PRNewswire) - - Alterations of the MET signaling pathway are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - New interim data from Phase II ...

Debiopharm International SA

Debiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial

Lausanne, Switzerland (ots) - First patient enrolled in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors Debiopharm (www.debiopharm.com) announced today the first patient enrolled in SMARTPLUS-106, an exploratory study investigating the safety and efficacy of ...

Philogen

Philogen Announces EUR62 Million Financing Round

EUR62M funding will be used to progress wholly-owned pipeline products through clinical development and expand manufacturing activities Dr. Guido Guidi, Dr. Roberto Ferraresi and Dr. Roberto Marsella join the board of directors Siena, Italy (ots/PRNewswire) - Philogen S.p.A (or the "Company"), a clinical-stage biotechnology company focused on antibody-based therapeutics, today is pleased to announce a EUR62 million ...

Merck Healthcare Germany GmbH

FDA Approves MAVENCLAD® (Cladribine) Tablets as First and Only Short-Course Oral Treatment for Relapsing-Remitting and Active Secondary Progressive Multiple Sclerosis

- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease - MAVENCLAD demonstrated significant efficacy across key measures of disease activity ...

Mundipharma EDO

Mundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer

FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future treatment option in this area of significant ...

Merck Healthcare Germany GmbH

Merck and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer

Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...

Mundipharma International

The expansion stage seeks to establish the overall response rate (ORR), duration of response (DR) and safety of five patient cohorts

Basel, Switzerland (ots/PRNewswire) - Mundipharma EDO GmbH, part of the Mundipharma global network of independent associated companies, today announced that the first patient has been enrolled in the expansion stage of a Phase I/II clinical trial of tinostamustine in patients with relapsed/refractory (R/R) ...

Merck Healthcare Germany GmbH

Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - - JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for ...

Merck Healthcare Germany GmbH

FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) in ...

Merck Healthcare Germany GmbH

Merck and GSK Announce Global Alliance to Jointly Develop and Commercialize M7824, a Novel Immunotherapy with Potential in Multiple Difficult-to-Treat Cancers

Not intended for US, Canada or UK-based media Darmstadt, Germany (ots/PRNewswire) - - Eight high priority immuno-oncology clinical development studies ongoing or expected to commence in 2019, including studies in non-small cell lung and biliary tract cancers - Merck will receive an upfront payment of EUR300 million ...

ProBioGen AG

ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

Berlin (ots/PRNewswire) - Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed milestone payment from Merus N.V. (Nasdaq: MRUS) based on Merus' grant of an exclusive license to ...

NORGINE B.V. and KOREA PHARMA CO., LTD.

NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

Amsterdam and Seoul, South Korea (ots/PRNewswire) - - Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE B.V. (Norgine), a leading European ...

Merck Healthcare Germany GmbH

Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the ...

Merck Healthcare Germany GmbH

Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - European Medicine Agency (EMA) grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer (BTC) - EMA orphan drug designation for M7824 in ...

Merck Healthcare Germany GmbH

Merck Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK - Agreement enables Merck to maintain an investment in the rapidly advancing oncology field of CAR-T, while focusing its R&D efforts - Intrexon to issue Merck $150 million of Intrexon stock and a $25 million convertible note; Intrexon to receive a $25 million cash investment ...

Merck Healthcare Germany GmbH

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of ...

Kyowa Kirin International PLC

Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome

Tokyo (ots/PRNewswire) - POTELIGEO will be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has received a European Commission decision granting a marketing authorisation to POTELIGEO® (Generic name: mogamulizumab), a ...

SAKK - Swiss Group for Clinical Cancer Research

The GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor, has awarded its science prize for the ninth time.

Merck Healthcare Germany GmbH

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared ...

Schweizerischer Nationalfonds / Fonds national suisse

Innovations in ultrasound imaging improve breast cancer detection

Bern (ots) - A new ultrasound technique can help distinguish benign breast tumours from malignant ones. The technology was developed with support from the Swiss National Science Foundation. Ultrasound is one of the three main technologies used in medical imaging. It is more compact and affordable than nuclear magnetic resonance imaging (MRI) techniques, and safer than x-rays. But the images it produces are often difficult ...

Janssen Pharmaceutica

New Phase 2 Data Show Stelara® (ustekinumab) Sustained Improvement in Disease Activity in Adults With Systemic Lupus Erythematosus Through One Year

Beerse, Belgium (ots/PRNewswire) - - Janssen presents one-year data from continued Phase 2 lupus study during plenary session at 2018 American College of Rheumatology (ACR) / Association for Rheumatology Health Professionals (ARHP) Annual Meeting The Janssen Pharmaceutical Companies of Johnson & Johnson today ...

Accuray Europe

Accuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018

Sunnyvale, California (ots/PRNewswire) - Building on its heritage of patient-first innovation, at this year's ASTRO (American Society for Radiation Oncology) Annual Meeting, Accuray Incorporated (NASDAQ: ARAY) will showcase radiation therapy solutions designed to enable clinicians to deliver truly personalized ...

European Society for Medical Oncology (ESMO)

Breast cancer patients use Twitter as a non-medical forum to share their experiences

Lugano/Munich (ots) - Twitter is a place where many cancer patients share and discuss their experiences, a study at the ESMO 2018 Congress reveals, based on analysis of the contents of over 6,000 tweets and retweets about breast cancer. The study was part of a larger, multidisciplinary project to observe the presence of different diseases on social media. The data ...

Janssen Pharmaceutica

Janssen to highlight data from broad rheumatology portfolio at the 2018 Annual meeting of the American College of Rheumatology

Beerse, Belgium (ots/PRNewswire) - - One-year results from the Phase 2 study evaluating STELARA® (ustekinumab) in patients with active systemic lupus erythematosus featured in a plenary presentation - 13 presentations from approved and pipeline products provide real-world treatment and disease insights across ...

Merck Healthcare Germany GmbH

Merck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF ?-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: 1845P; ...

Kyowa Kirin International PLC

Kyowa Kirin Presents Data at EORTC-Cutaneous Lymphoma Task Force Meeting Showing Significantly Improved Quality of Life for Patients With Mycosis Fungoides (MF) and Sézary Syndrome (SS) on Mogamulizumab

Tokyo (ots/PRNewswire) - First oral presentation of Quality of Life data from the phase III trial (MAVORIC), the largest randomised trial in MF and SS - the two most common types of Cutaneous T Cell Lymphoma[1] Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces that Quality of Life (QoL) data from the pivotal ...

Merck Healthcare Germany GmbH

BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...

Genomic Health, Inc.

German Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® Has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results

Geneva (ots/PRNewswire) - Updated Assessment of Breast Cancer Gene Expression Profiling Tests for Clinical Use in Germany Final German Federal Joint Committee (G-BA) Reimbursement Decision Expected by End of 2018 Genomic Health today announced the publication of an updated assessment ...